Arrowhead 制药 ARWR
$58.16 +$0.70 (+1.22%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $58.16 0.00%
开盘$58.21
昨收$57.46
当日区间$57.00 – $58.71
成交量1.36M
市值$8.22B
市盈率（TTM）–
股息率–
财报
财报日平均波动±9.6%近16次财报
收涨次数7 / 1644% 的概率
最佳反应+24.2%
最差反应-26.8%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q3 | 4 Aug 2026 | After Market | ±8.9% | -2.99% | 符合区间 |
| 2026/Q2 | 7 May 2026 | After Market | ±7.3% | -6.75% | 符合区间 |
| 2026/Q1 | 5 Feb 2026 | After Market | ±11.9% | -0.19% | 符合区间 |
| 2025/Q4 | 25 Nov 2025 | After Market | ±13.5% | +23.34% | 超出定价预期 |
| 2025/Q3 | 7 Aug 2025 | After Market | ±13.3% | +2.24% | 符合区间 |
| 2025/Q2 | 12 May 2025 | After Market | ±12.0% | +9.38% | 符合区间 |
| 2025/Q1 | 10 Feb 2025 | After Market | ±10.8% | -5.17% | 符合区间 |
| 2024/Q4 | 26 Nov 2024 | After Market | ±15.0% | +24.23% | 超出定价预期 |
| 2024/Q3 | 8 Aug 2024 | After Market | ±12.7% | -9.44% | 符合区间 |
| 2024/Q2 | 9 May 2024 | After Market | ±10.4% | -10.68% | 超出定价预期 |
| 2023/Q4 | 29 Nov 2023 | After Market | ±12.0% | -26.85% | 超出定价预期 |
| 2023/Q3 | 7 Aug 2023 | After Market | ±8.9% | -10.78% | 超出定价预期 |
| 2023/Q2 | 2 May 2023 | After Market | ±16.4% | +13.62% | 符合区间 |
| 2023/Q1 | 6 Feb 2023 | After Market | ±14.3% | +0.33% | 符合区间 |
| 2022/Q4 | 28 Nov 2022 | After Market | ±20.5% | +7.11% | 符合区间 |
| 2022/Q3 | 4 Aug 2022 | After Market | ±14.1% | -0.37% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
基本面
最新报告季度：Q3, ended Jun 2026
营收$75.25M+171.0% YoY
营业利润-$170.09M-2.7% YoY
净利润-$178.92M-0.1% YoY
摊薄每股收益-$1.36-7.9% YoY
自由现金流-$181.32M-15.4% YoY
经营现金流-$177.47M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
营业利润率-33.8%
净利率-47.8%
净资产收益率-64.8%
资产收益率-18.3%
投入资本回报率-25.5%
流动比率5.90
负债/资产比率77.9%
现金及投资$1.60B
总负债$978.37M
净现金（净负债）$623.59M
暂无评论——快来第一个聊聊 ARWR。